Eastside Clinical Research Los Angeles, CA - 90022

Eastside Clinical Research is categorized under Clinics in Los Angeles, CA and active since 2008.

Eastside Clinical Research was established in 2008, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Clinics business, which does work in the B2C market, and is classified as a Clinics, under code number 6214930 by the NAICS.

If you are seeking more information, feel free to contact Enrique Gonzales, Manager at the company’s single location by writing to 4755 East Cesar East Chavez Avenue # A, Los Angeles, California CA 90022 or by phoning (323) 261-4706. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Eastside Clinical Research
Contact Person: Enrique Gonzales, Manager
Address: 4755 East Cesar East Chavez Avenue # A, Los Angeles, California 90022
Phone Number: (323) 261-4706
Annual Revenue (USD): $1.000.000 to $2.499.999
Founded: 2008
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Clinics
SIC Code: 8011
NAICS Code: 6214930
Share This Business:

Eastside Clinical Research was started in 2008 to provide professional Clinics under the SIC code 8011 and NAICS code 6214930. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.

Feel free to contact Enrique Gonzales, Manager for inquiries that concern Eastside Clinical Research by calling the company number (323) 261-4706, as your correspondence is most welcome. Additionally, the physical location of the single location of Eastside Clinical Research can be found at the coordinates 34.04064,-118.16299 as well as the street address 4755 East Cesar East Chavez Avenue # A in Los Angeles, California 90022.

For its online presence, you may visit Eastside Clinical Research’s website at and engage with its social media outlets through on Twitter and on Facebook.